Table 2. Clinical characteristics of T-PLL in previously reported series.
| Matutes (1) | Matutes (5) | Garand (9)a | Garand (9)b | Ravandy (48) | |
|---|---|---|---|---|---|
| Number of patients | 78 | 29 | 53 | 25 | 57 |
| Age (y) median | 69 | 69 | 69 | 72 | 63 |
| B symptoms | 66 | 11 | |||
| Splenomegaly (%) | 73 | 82 | 81 | 11 | 42 |
| Lymphadenopathy (%) | 53 | 46 | 64*/28** | 0 | 47 |
| Hepatomegaly (%) | 40 | 42 | 43 | 5 | 24 |
| Skin lesions (%) | 27 | 25 | 25 | 0 | |
| Serous effusions (%) | 14 | 21 | 19 | 0 | |
| Other extra-nodal site (%) | 13 | 0 | |||
| WBC (> 100 × 109/L (%) | 75 | 82 | 70 | 0 | |
| WBC: 100 × 109/L (median) | 164 | 19 | 144 | ||
| Hemoglobin < 10 g/dl (%) | 36 | 55 | 15 | 0 | |
| Hemoglobin: g/dl (median) | 11.8 | ||||
| Platelets < 100 × 109/l (%) | 51 | 68 | 36 | 10 | |
| Platelets: 100 × 109/l(median) | 85 |
aAggressive forms, bIndolent forms, *Peripheral lymphadenopathy, ** Abdominal or hilar lymphadenopathy, which will open the way for targeted therapies